On-Demand Webinar featuring Dr Elizabeth Crone, Business Development Manager at Owlstone & Dr Hsuan (Tina) Chou, Biomarker Scientist at Owlstone

Current and upcoming gene editing technologies, such as prime editing and cell line models, have huge potential in applications such as cancer treatment. With the field constantly witnessing new breakthroughs and advances, genome modification holds a lot of promise for the future.

Cancer-related cognitive impairment in young adults found pre-treatment, study reports.

Unique neuroinflammatory signatures and pathways present in tauopathies could provide greater insight into distinct mechanisms of disease.

How can we better define patient-centric clinical trials within the drug development process?

The therapeutic targeting of TME microglia activity may improve the efficacy of treatments for melanoma brain metastasis. Future research could represent a new opportunity in confronting one of the most difficult cancers to treat.

Your front-row seat to world innovators

Study finds predictive link between genital herpes and HIV.

A new study by Cedars-Sinai could identify protein biomarkers for preeclampsia.

The potential oncolytic applications of Salmonella ZH9 include its use in mitigating diseases such as bladder cancer, with a demonstrated therapeutic effect in cancer models.

Christopher Conn, Director of Diagnostics Strategy at Amgen, leads a Discussion Group on patient testing and engagement in biomarker clinical trials.

Multiplex immunofluorescence is gaining prevalence in oncology diagnostics; what makes it so effective, and how is it being brought into the clinic?